Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) Greg Madison joins Proactive London after announcing 2021 revenues will be in line with expectations at £1.5mln as it made the first sales of its breakthrough drug for iron deficiency.
As Madison explains the US is key right now as it looks to roll out its ferric maltol product, which is known as Accrufer in the States and Feraccru elsewhere.
He says the priorities for the US launch of Accrufer were to increase awareness, generate clinical experience, and expand payer coverage, and we have made significant progress across each of these priorities.